- Home
- BTX vs RLAY Comparison
BTX vs RLAY Comparison
Compare BTX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTX | RLAY |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.3M | 4.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTX | RLAY |
|---|---|---|
| Price | $8.96 | $18.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 436.8K | ★ 2.2M |
| Earning Date | 11-01-2025 | 05-05-2026 |
| Dividend Yield | ★ 9.94% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $6.13 | $3.89 |
| 52 Week High | $9.44 | $21.27 |
Technical Indicators
Market Signals| Indicator | BTX | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 58.63 | 45.13 |
| Support Level | $8.60 | $18.00 |
| Resistance Level | $9.40 | $20.82 |
| Average True Range (ATR) | 0.17 | 0.80 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 47.26 | 28.24 |
Price Performance
Historical ComparisonAbout BTX BlackRock Technology and Private Equity Term Trust
BlackRock Technology and Private Equity Term Trust is a closed-end management investment company. Its investment objectives are to provide total return and income through long-term capital appreciation.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.